Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Xarelto: Investigational Agent for Treatment and Prevention of Thromboembolic Events

Venous thromboembolism is a condition in which clots form in the deep veins of the leg, rupture and enter the pulmonary artery. It is the third most common cardiovascular disease.



  • Venous thromboembolism is the third most common cardiovascular disease.
  • A molecule of Xarelto
  • Activated Factor X
  • Xarelto (rivaroxaban)

Go Top